北京若生智能科技有限公司
Drug Database
HU

human normal immunoglobulin G (NPB01)

✓ Approved

Nihon Pharmaceutical · 多克隆抗体 · 多克隆抗体

什么是 human normal immunoglobulin G？

human normal immunoglobulin G 是一种多克隆抗体，由Nihon Pharmaceutical研发。该药已获批，用于治疗相关适应症，给药途径：Injectable (Others)、Intravenous (IV)。

药物档案

商品名NPB01
公司Nihon Pharmaceutical
药物类别多克隆抗体, 抗体
给药途径Injectable (Others), Intravenous (IV)
状态Approved
来源： ClinicalTrials.gov, Nihon Pharmaceutical

治疗适应症

human normal immunoglobulin G 针对 11 个适应症，涉及 5 个治疗领域。

治疗领域疾病/病症分期
Skin and subcutaneous tissue disordersErythema multiforme✓ Approved
Nervous system disordersGuillain-Barre syndrome✓ Approved
Skin and subcutaneous tissue disordersPemphigoid✓ Approved
Skin and subcutaneous tissue disordersPemphigus✓ Approved
Infections and infestationsSalmonellosis✓ Approved

注册免费账户还可查看另外 6 个适应症

免费注册查看全部适应症 →

相关研究文献

PubMedTranslational pediatrics2026-09-11

Traditional Chinese medicine combined with conventional Western medicine for chronic cough following respiratory infection in children: a systematic review and meta-analysis.

Cui Shengtao S, Xie Xiaofei X, Yang Jingjing J, Xiao Yao Y et al.

Chronic cough following respiratory infection in children is often refractory to conventional therapies. However, the current clinical evidence regarding the efficacy of traditional Chinese medicine (TCM) remains inconclusive and lacks systematic synthesis, leaving clinicians without clear guidance. This study systematically evaluated the efficacy and safety of TCM for chronic cough following respiratory infection in children to support clinical decision-making. A systematic search was conducted in the Cochrane Library, PubMed, Embase, Web of Science, Wiley Online Library, China National Knowledge Infrastructure (CNKI), and Wanfang databases. Randomized controlled trials (RCTs) of TCM for chronic cough following respiratory infection in children were included. Meta-analyses were performed using RevMan 5.4 and Stata 16.0. A total of 23 RCTs involving 2,126 children were included. Meta-analysis demonstrated that, compared with conventional Western medical treatment alone, TCM combined with conventional treatment significantly improved the overall clinical effectiveness rate [risk ratio (RR) =1.19, 95% confidence interval (CI) (1.15, 1.24), P<0.001], shortened the time to cough resolution [mean difference (MD) =-3.19, 95% CI (-4.42, -1.97), P<0.001] and the time to disappearance of pulmonary rales [MD =-2.00, 95% CI (-2.47, -1.54), P<0.001], and significantly reduced cough symptom scores [MD =-1.32, 95% CI (-1.69, -0.95), P<0.001]. For secondary outcomes, combined TCM therapy significantly reduced TCM syndrome scores, improved immune function indicators [immunoglobulin A (IgA), immunoglobulin M (IgM), and immunoglobulin G (IgG)], and decreased levels of inflammatory biomarkers [C-reactive protein (CRP), interleukin-6 (IL-6), tumor necrosis factor-alpha (TNF-α), and monocyte chemoattractant protein-4 (MCP-4)]. No statistically significant difference was observed between groups in the incidence of adverse events. TCM used as an adjunct to conventional Western medical treatment may provide additional benefits in improving clinical outcomes and alleviating symptoms in children with post-infectious chronic cough. However, due to limitations in study quality and heterogeneity, further high-quality, well-designed studies are warranted to strengthen the evidence base.

PMID 42724356
阅读全文 →
PubMedScientific reports2026-09-11

Enrichment of rhenium, uranium and tantalum in jurassic coal from yili basin, xinjiang - evidence from mineralogy and geochemistry.

Bai Hongyang H, Wang Wenfeng W, Feng Shuo S, Wang Maomao M et al.

In this study, detailed geochemical and mineralogical investigations were conducted on the No.12 coal from the Early-Middle Jurassic in the Yili Basin. The results indicate the following: (a) The No.12 coal from the southern Yili Basin exhibits super-elevated enrichment (100 < concentration coefficient, CC) of Re(394.02ng/g), U(285.99 µg/g), and Ta(120.51 µg/g); high enrichment (10 < CC < 100) of Mo(29.11 µg/g), Se(28.51 µg/g) and Hf(12.54 µg/g); enrichment (5 < CC < 10) of Zn (7.86 µg/g)and Be (7.62 µg/g); slight enrichment (2 < CC < 5) of Cs (4.78 µg/g), Rb (4.75 µg/g), V (4.64 µg/g), Cr (4.51 µg/g), Co (4.01 µg/g), Ni (3.67 µg/g), W (3.65 µg/g), Pb (3.35 µg/g), Ge (2.96 µg/g), Cd (2.96 µg/g), F (2.70 µg/g), Cu(2.64 µg/g) Tl(2.53 µg/g), In(2.46 µg/g), Ga(2.41 µg/g), Sb(2.32 µg/g), Zr(2.31 µg/g), Sc(2.28 µg/g), and Th(2.18 µg/g); normal abundance (0.5 < CC < 2) of As(1.93 µg/g), Nb(1.75 µg/g), Li(1.42 µg/g), Hg(1.30 µg/g), Ba(1.12 µg/g), Sr(0.84 µg/g), and B(0.67 µg/g); and depletion(CC < 0.5) of Bi (0.40 µg/g). Excluding volatilization during combustion, U, Re, and Ta in the coal ash have certain resource potential to some extent. (b) The most common minerals in the No.12 coal are quartz, kaolinite, and pyrite. Additionally, some uncommon minerals, such as rutile, monazite, barite, clausthalite, ferroselite, pyrrhotite, coffinite, uraninite, sphalerite, and Fe-sulfate, were identified in the coal with super-elevated U content (especially when the U content exceeds 1000 µg/g). Among these minerals, clausthalite, ferroselite, and uraninite can control the enrichment of inorganic U and Se. (c) The enrichment of U-Re-Se-Mo-Ta-Hf in the No.12 coal is probably attributed to the infiltration of U-bearing oxidized solutions and the input of detritus containing critical metal elements from the sedimentary provenance.

PMID 42722711
阅读全文 →
PubMedSpinal cord2026-09-11

A new self-efficacy scale for people with a spinal cord injury; The General and Spinal Cord Injury Specific Self-efficacy Scale (G-SCI-SeS).

van Diemen Tijn T, van Nes Ilse J W IJW, de Klerk Erik E, Scholten Eline W M EWM et al.

A longitudinal cohort. This study aimed to be the first validation of the General and Spinal Cord Injury Specific Self-efficacy Scale (G-SCI-SeS), designed to capture both trait-like (general) and state-like (disease or SCI-specific) dimensions of self-efficacy (SE). Participants were followed from post-acute rehabilitation up to five years after discharge in the Netherlands. In the latest follow-up of a longitudinal spinal cord injury cohort, the G-SCI-SeS was administered alongside a general SE scale, two disease-specific SE scales, a distress scale and a life satisfaction scale. Among 142 participants with complete data, confirmatory factor analyses supported a two-factor structure, which demonstrated superior fit compared to a one-factor model. Internal consistency was excellent for the total score and General SE subscale, and good for the SCI-specific subscale. No floor effects and minimal ceiling effects were observed. Score distributions were non-normal, with a tendency toward higher values for all SE scales. Intercorrelations between the G-SCI-SeS and other SE scales were strong, even where moderate correlations were hypothesized. The G-SCI-SeS demonstrated a robust two-factor structure and moderate-to-good construct validity. Strong correlations between trait and state SE measures may reflect convergence of these constructs in the chronic phase of SCI. Developed through an iterative process incorporating cognitive interviews, the G-SCI-SeS appears suitable for clinical and research use. Further studies should investigate other forms of validity and the sensitivity of the G-SCI-SeS to change from the sub-acute phase to the chronic phase.

PMID 42722708
阅读全文 →
PubMedThe British journal of dermatology2026-09-11

Efficacy and safety of subcutaneous efgartigimod with prednisone in moderate-to-severe pemphigus (ADDRESS): a global, phase III, randomised controlled, double-blind trial.

Joly Pascal P, Murrell Dedee F DF, Aoyama Yumi Y, Caux Frédéric F et al.

Pemphigus vulgaris (PV) and pemphigus foliaceus (PF) are rare, chronic, potentially life-threatening, immunoglobulin (Ig)G-mediated, autoimmune skin and/or mucosal blistering diseases. Efgartigimod, a human IgG1 antibody Fc fragment, blocks the neonatal Fc receptor, decreasing IgG recycling and reducing both healthy and pathogenic IgG autoantibody levels. To investigate the efficacy, safety and impact of subcutaneous efgartigimod PH20 (co-formulated with recombinant human hyaluronidase PH20) in conjunction with prednisone in the treatment of pemphigus. Adult participants with newly diagnosed or relapsing moderate-to-severe pemphigus were recruited in this phase III, prospective, multicentre, randomised, double-blinded, placebo-controlled study (NCT04598451). Participants were randomised (2 : 1) to weekly subcutaneous efgartigimod PH20 or placebo. Subcutaneous efgartigimod PH20 2000 mg was administered on days 1 and 8, followed by 1000 mg weekly until complete remission on minimal prednisone therapy (CRmin) (≤ 10 mg daily). All participants received concomitant prednisone starting at 0.5 mg kg-1 daily. The primary outcome was the proportion of participants with PV who achieved CRmin by week 30, while receiving minimal prednisone, for ≥ 8 weeks. Pharmacodynamics and safety were also assessed. Overall, 222 participants (PV: n = 190; PF: n = 32) were randomised (subcutaneous efgartigimod PH20: n = 147; placebo: n = 75). The proportions of participants with PV achieving CRmin within 30 weeks were comparable between the subcutaneous efgartigimod PH20 and placebo groups, with no statistically significant difference observed [44/124 (35.5%) vs. 20/66 (30.3%); P = 0.60; odds ratio 1.19 (95% confidence interval 0.60-2.41)]. Total prednisone consumption over time was comparable between groups. Subcutaneous efgartigimod PH20 resulted in rapid reductions from baseline in total IgG and anti--desmoglein-1 and anti-desmoglein-3 autoantibody levels, but these did not translate to improvements in Pemphigus Disease Area Index scores. The rates of adverse events (AEs) in the subcutaneous efgartigimod PH20 and placebo groups were 89.1% (n = 131/147) and 76.0% (n = 57/75), respectively; most were mild to moderate [serious AEs: 12.2% (n = 18/147) and 13.3% (n = 10/75), respectively]. No deaths occurred. Subcutaneous efgartigimod PH20 in combination with systemic corticosteroids did not demonstrate clinical benefit over systemic corticosteroids alone in patients with moderate-to-severe pemphigus at 30 weeks, but it was well tolerated in this patient population.

PMID 42723554
阅读全文 →
PubMedDisability and rehabilitation. Assistive technology2026-09-11

Pilot analysis of forces that can destabilise occupied manual wheelchairs on low-floor public transit buses.

Unsworth Carolyn Anne CA, Jayawardena Amal A, Timmer Amanda Jane AJ, Kahandawa Appuhamillage Gayan G

Prior to identifying optimal restraint or containment systems to prevent people using manual wheelchairs sliding or tipping on large public transit buses, the forces that destabilise them must be understood. This pilot study documented the (1) forces that wheelchairs experience on buses, (2) movement of wheelchairs on buses, and (3) differences between normal operating forces and the forces that lead to a wheelchair sliding or tipping. Methods: Data on the forces that acted on three manual wheelchairs were gathered using accelerometers across six bus routes with varied terrain. Data ranges were summarised using MATLAB, and Rainflow analysis generated graphs for visual inspection. The points at which wheelchairs began to slide, and tip were modelled and simulated in 3D in SOLIDWORKS and MSC Adams software respectively. Direct comparisons were then made between normal operating forces and the forces that lead to slide or tip. Real-world driving forces that act on wheelchairs under typical driving conditions ranged from -0.62 g to 0.44 g. The points at which wheelchairs began to slide or tip were documented. A table showing normal operating forces and the forces that lead to slide or tip was prepared confirming slide and tip can occur across regular manoeuvres, although such forces are rarely generated. Conclusion: These pilot data inform bus designers, operators, and transport policymakers of the forces that act on manual wheelchairs that produce slide or tip so that driver behaviour can be monitored and restraint or containment systems can be continually improved, thereby promoting safety for all passengers.

PMID 42723331
阅读全文 →
PubMedChembiochem : a European journal of chemical biology2026-09-11

N8-Modified Quino[4,3,2-Kl]acridines as Promising Antimalarial G-Quadruplex Ligands.

Saulnier Steve S, Gomes Marco Antônio G B MAGB, Salim Mariam M, Guichonnet Maxime M et al.

To face the increasing multidrug resistance of the malaria parasite Plasmodium falciparum, the development of new compounds that act in novel ways is urgent. G-quadruplexes (G4), Guanine-rich secondary structures of DNA and RNA sequences, have an essential role in cell survival and cell metabolism regulation, including in Plasmodium. We have recently demonstrated that the G-quadruplex ligand RHPS4, an acridine derivative, displays strong antiplasmodial activity by disrupting P. falciparum through G4 stabilization, leading to parasite death. Based on this original mode of action, we propose here a series of new RHPS4 analogues. These derivatives were then tested against P. falciparum and on human cells to evaluate their selectivity index. They exhibited IC50 values ranging from 70 nM to up to 10 µM with cationic analogues more active than neutral ones. Their ability to interact and stabilize G-quadruplex DNA structures was also evaluated. Among all RHPS4 analogues, the compound 8b (N8-ethyl) exhibited the best activity (70 nM), a high selectivity index (143), and a significant capacity to stabilize the G4 structures.

PMID 42723250
阅读全文 →

注册免费账户还可查看另外 9996 篇文献

免费注册查看全部文献 →

了解更多human normal immunoglobulin G